JP2010520875A - Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 - Google Patents
Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 Download PDFInfo
- Publication number
- JP2010520875A JP2010520875A JP2009552762A JP2009552762A JP2010520875A JP 2010520875 A JP2010520875 A JP 2010520875A JP 2009552762 A JP2009552762 A JP 2009552762A JP 2009552762 A JP2009552762 A JP 2009552762A JP 2010520875 A JP2010520875 A JP 2010520875A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- hydroxy
- dihydro
- ethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 299
- 101710189965 P2X purinoceptor 7 Proteins 0.000 title claims description 5
- 102100037602 P2X purinoceptor 7 Human genes 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 claims abstract description 41
- 208000002193 Pain Diseases 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 31
- 230000036407 pain Effects 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 22
- 241000124008 Mammalia Species 0.000 claims abstract description 21
- 230000001154 acute effect Effects 0.000 claims abstract description 19
- 230000001404 mediated effect Effects 0.000 claims abstract description 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract description 16
- 206010061218 Inflammation Diseases 0.000 claims abstract description 15
- 230000004054 inflammatory process Effects 0.000 claims abstract description 15
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 14
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 12
- 208000010125 myocardial infarction Diseases 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 12
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 12
- 230000009529 traumatic brain injury Effects 0.000 claims abstract description 12
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 11
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 10
- 206010003246 arthritis Diseases 0.000 claims abstract description 9
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 9
- 230000002159 abnormal effect Effects 0.000 claims abstract description 7
- 208000014674 injury Diseases 0.000 claims abstract description 3
- -1 hydroxy, amino Chemical group 0.000 claims description 153
- 125000000217 alkyl group Chemical group 0.000 claims description 120
- 125000003118 aryl group Chemical group 0.000 claims description 89
- 238000000034 method Methods 0.000 claims description 87
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 73
- 238000006243 chemical reaction Methods 0.000 claims description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 64
- 125000001072 heteroaryl group Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 43
- 229910052731 fluorine Inorganic materials 0.000 claims description 41
- 239000001257 hydrogen Substances 0.000 claims description 41
- 125000003545 alkoxy group Chemical group 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 38
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 37
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 32
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 27
- 229910052801 chlorine Inorganic materials 0.000 claims description 26
- 208000035475 disorder Diseases 0.000 claims description 26
- 208000004296 neuralgia Diseases 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 24
- 239000002253 acid Substances 0.000 claims description 23
- 239000000651 prodrug Substances 0.000 claims description 20
- 229940002612 prodrug Drugs 0.000 claims description 20
- 125000001475 halogen functional group Chemical group 0.000 claims description 18
- 239000012453 solvate Substances 0.000 claims description 18
- 125000002252 acyl group Chemical group 0.000 claims description 17
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 17
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 16
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 15
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 15
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 15
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 14
- 125000004442 acylamino group Chemical group 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 13
- 208000037765 diseases and disorders Diseases 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 13
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- 125000002947 alkylene group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 12
- 150000001540 azides Chemical class 0.000 claims description 12
- 208000006673 asthma Diseases 0.000 claims description 11
- 208000003251 Pruritus Diseases 0.000 claims description 10
- 206010046851 Uveitis Diseases 0.000 claims description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- 201000008482 osteoarthritis Diseases 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 10
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- 206010015037 epilepsy Diseases 0.000 claims description 9
- 210000005036 nerve Anatomy 0.000 claims description 9
- 208000023504 respiratory system disease Diseases 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000006217 methyl sulfide group Chemical group [H]C([H])([H])S* 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 125000004076 pyridyl group Chemical group 0.000 claims description 8
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 8
- 206010065390 Inflammatory pain Diseases 0.000 claims description 7
- 208000019695 Migraine disease Diseases 0.000 claims description 7
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 206010043269 Tension headache Diseases 0.000 claims description 7
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 7
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 7
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 7
- 206010027599 migraine Diseases 0.000 claims description 7
- RKIHNKBYTUYHDG-CYBMUJFWSA-N n-[2-[(2r)-1-aminopropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CN)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 RKIHNKBYTUYHDG-CYBMUJFWSA-N 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 208000004371 toothache Diseases 0.000 claims description 7
- KGUURNWYZWNORB-GFCCVEGCSA-N (2r)-2-[6-methoxy-1-oxo-5-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]isoquinolin-2-yl]propanamide Chemical compound COC1=CC=C(C(N([C@H](C)C(N)=O)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 KGUURNWYZWNORB-GFCCVEGCSA-N 0.000 claims description 6
- JECILOFRRYCNDH-CYBMUJFWSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 JECILOFRRYCNDH-CYBMUJFWSA-N 0.000 claims description 6
- 208000019901 Anxiety disease Diseases 0.000 claims description 6
- 208000006561 Cluster Headache Diseases 0.000 claims description 6
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 206010019233 Headaches Diseases 0.000 claims description 6
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 6
- 230000036506 anxiety Effects 0.000 claims description 6
- 230000036772 blood pressure Effects 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 231100000869 headache Toxicity 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 150000002632 lipids Chemical class 0.000 claims description 6
- FMOOSLMLRAUSBH-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 FMOOSLMLRAUSBH-LLVKDONJSA-N 0.000 claims description 6
- SOXLIWHVZZQEKK-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 SOXLIWHVZZQEKK-LLVKDONJSA-N 0.000 claims description 6
- GFMGLRZDRMQUJJ-CYBMUJFWSA-N n-[6-cyclopropyl-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound C1CC1C1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 GFMGLRZDRMQUJJ-CYBMUJFWSA-N 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 201000000980 schizophrenia Diseases 0.000 claims description 6
- 208000019116 sleep disease Diseases 0.000 claims description 6
- OHYAXGAMZSGPOJ-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-(2-hydroxyethylamino)-1-oxoisoquinolin-5-yl]acetamide Chemical compound OCCNC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F OHYAXGAMZSGPOJ-UHFFFAOYSA-N 0.000 claims description 5
- QGYFHOFGDBIVEE-HNNXBMFYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-1-oxo-2-[(3s)-pyrrolidin-3-yl]isoquinolin-5-yl]acetamide Chemical compound C=1C=C(C(F)(F)F)C(F)=CC=1CC(=O)NC=1C(C)=CC=C(C2=O)C=1C=CN2[C@H]1CCNC1 QGYFHOFGDBIVEE-HNNXBMFYSA-N 0.000 claims description 5
- GTJKHIXCDWFPNM-ABWNMTHHSA-N 6-chloro-n-[(3-hydroxy-3-bicyclo[2.2.1]heptanyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)C(C2)CCC2C1 GTJKHIXCDWFPNM-ABWNMTHHSA-N 0.000 claims description 5
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims description 5
- 208000020925 Bipolar disease Diseases 0.000 claims description 5
- 206010069632 Bladder dysfunction Diseases 0.000 claims description 5
- 208000034347 Faecal incontinence Diseases 0.000 claims description 5
- 208000014540 Functional gastrointestinal disease Diseases 0.000 claims description 5
- 206010026749 Mania Diseases 0.000 claims description 5
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims description 5
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 5
- 206010046543 Urinary incontinence Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 5
- 201000010105 allergic rhinitis Diseases 0.000 claims description 5
- 201000007637 bowel dysfunction Diseases 0.000 claims description 5
- 208000010877 cognitive disease Diseases 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 206010014599 encephalitis Diseases 0.000 claims description 5
- 230000009610 hypersensitivity Effects 0.000 claims description 5
- 230000007803 itching Effects 0.000 claims description 5
- 208000017169 kidney disease Diseases 0.000 claims description 5
- 230000027939 micturition Effects 0.000 claims description 5
- 201000006417 multiple sclerosis Diseases 0.000 claims description 5
- CUGAKOQXTULJDP-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-[4-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 CUGAKOQXTULJDP-UHFFFAOYSA-N 0.000 claims description 5
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 230000000241 respiratory effect Effects 0.000 claims description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 5
- VAGQFUYFCXXJAL-LYTYMJBXSA-N (2r)-2-[5-[[2-(1-adamantyl)acetyl]amino]-6-chloro-1-oxoisoquinolin-2-yl]propanamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=C2C=CN([C@@H](C(N)=O)C)C(=O)C2=CC=C1Cl VAGQFUYFCXXJAL-LYTYMJBXSA-N 0.000 claims description 4
- VIFCIENBDYQQDX-LLVKDONJSA-N (2r)-2-[6-chloro-1-oxo-5-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]isoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 VIFCIENBDYQQDX-LLVKDONJSA-N 0.000 claims description 4
- OPGCMPGPBPRTCR-SNVBAGLBSA-N (2r)-2-[6-chloro-5-[[2-(4-chloro-2-fluorophenyl)acetyl]amino]-1-oxoisoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C=C1F OPGCMPGPBPRTCR-SNVBAGLBSA-N 0.000 claims description 4
- MZMRGDSURPETPD-SNVBAGLBSA-N (2r)-2-[6-chloro-5-[[2-[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]amino]-1-oxoisoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F MZMRGDSURPETPD-SNVBAGLBSA-N 0.000 claims description 4
- VIFCIENBDYQQDX-NSHDSACASA-N (2s)-2-[6-chloro-1-oxo-5-[[2-[4-(trifluoromethyl)phenyl]acetyl]amino]isoquinolin-2-yl]propanamide Chemical compound ClC1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 VIFCIENBDYQQDX-NSHDSACASA-N 0.000 claims description 4
- WKSFDYRQJMJNFR-NWDGAFQWSA-N (2s)-n-[2-[(2r)-1-amino-1-oxopropan-2-yl]-6-chloro-1-oxoisoquinolin-5-yl]-2-(4-chlorophenyl)propanamide Chemical compound C1([C@@H](C(=O)NC=2C3=C(C(N([C@H](C)C(N)=O)C=C3)=O)C=CC=2Cl)C)=CC=C(Cl)C=C1 WKSFDYRQJMJNFR-NWDGAFQWSA-N 0.000 claims description 4
- UFSZNGPKJWFSHR-CYBMUJFWSA-N 2-(4-chloro-3-fluorophenyl)-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(F)=C1 UFSZNGPKJWFSHR-CYBMUJFWSA-N 0.000 claims description 4
- NNKBOZOTRMTPFO-LLVKDONJSA-N 2-(4-chloro-3-fluorophenyl)-n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(F)=C1 NNKBOZOTRMTPFO-LLVKDONJSA-N 0.000 claims description 4
- LKZDPAFXWXYVCK-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F LKZDPAFXWXYVCK-UHFFFAOYSA-N 0.000 claims description 4
- VSGLANORJMNZRC-CYBMUJFWSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F VSGLANORJMNZRC-CYBMUJFWSA-N 0.000 claims description 4
- BDROBZBNYQZUKM-GFCCVEGCSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methoxy-1-oxoisoquinolin-5-yl]acetamide Chemical compound COC1=CC=C(C(N([C@H](C)CO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 BDROBZBNYQZUKM-GFCCVEGCSA-N 0.000 claims description 4
- FFEPLNNDVFVTTR-QGZVFWFLSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-1-oxo-2-[(2r)-1-piperazin-1-ylpropan-2-yl]isoquinolin-5-yl]acetamide Chemical compound C([C@@H](C)N1C(C2=CC=C(C)C(NC(=O)CC=3C=C(F)C(=CC=3)C(F)(F)F)=C2C=C1)=O)N1CCNCC1 FFEPLNNDVFVTTR-QGZVFWFLSA-N 0.000 claims description 4
- PSTNSIKFKNCGHB-CQSZACIVSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-2-[(2r)-1-(methylamino)propan-2-yl]-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@H](C)CNC)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 PSTNSIKFKNCGHB-CQSZACIVSA-N 0.000 claims description 4
- UTSFTJWRTXSFSI-CYBMUJFWSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 UTSFTJWRTXSFSI-CYBMUJFWSA-N 0.000 claims description 4
- BHWBPMXJZHATJD-HNNXBMFYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-n-[6-methyl-1-oxo-2-[(3s)-pyrrolidin-3-yl]isoquinolin-5-yl]acetamide Chemical compound C=1C=C(F)C(C(F)(F)F)=CC=1CC(=O)NC=1C(C)=CC=C(C2=O)C=1C=CN2[C@H]1CCNC1 BHWBPMXJZHATJD-HNNXBMFYSA-N 0.000 claims description 4
- ASENOMBGSSJKRC-MRXNPFEDSA-N 2-cycloheptyl-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1CCCCCC1 ASENOMBGSSJKRC-MRXNPFEDSA-N 0.000 claims description 4
- BEMQUFQRXPAIGV-CQSZACIVSA-N 6-chloro-n-[(1-hydroxycycloheptyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)CCCCCC1 BEMQUFQRXPAIGV-CQSZACIVSA-N 0.000 claims description 4
- CAEONLAMIOORMA-GFCCVEGCSA-N 6-chloro-n-[(4,4-difluorocyclohexyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1CCC(F)(F)CC1 CAEONLAMIOORMA-GFCCVEGCSA-N 0.000 claims description 4
- VTYGNFUYVGHQRP-LLVKDONJSA-N 6-chloro-n-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(C(F)(F)F)C(F)=C1 VTYGNFUYVGHQRP-LLVKDONJSA-N 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 201000009961 allergic asthma Diseases 0.000 claims description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- AFSOBVSIITWGAF-CQSZACIVSA-N n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]-2-[4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1 AFSOBVSIITWGAF-CQSZACIVSA-N 0.000 claims description 4
- IZEFXOBBYMQCBC-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-(3,4-dichlorophenyl)acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 IZEFXOBBYMQCBC-UHFFFAOYSA-N 0.000 claims description 4
- XJRFFZIYWHIBPY-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-[2-fluoro-3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F XJRFFZIYWHIBPY-UHFFFAOYSA-N 0.000 claims description 4
- ZXOKHTSAKAOOLZ-UHFFFAOYSA-N n-[6-chloro-2-(2-hydroxyethyl)-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 ZXOKHTSAKAOOLZ-UHFFFAOYSA-N 0.000 claims description 4
- OTKCYGCETOSQLA-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-(3,4-dichlorophenyl)acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 OTKCYGCETOSQLA-LLVKDONJSA-N 0.000 claims description 4
- LAUUQYWKAHXBPX-LLVKDONJSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[2-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C=C1F LAUUQYWKAHXBPX-LLVKDONJSA-N 0.000 claims description 4
- XOUBDCKHGLMWMZ-CYBMUJFWSA-N n-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(C(F)(F)F)C(F)=C1 XOUBDCKHGLMWMZ-CYBMUJFWSA-N 0.000 claims description 4
- 230000003959 neuroinflammation Effects 0.000 claims description 4
- 208000036273 reactive airway disease Diseases 0.000 claims description 4
- 230000011514 reflex Effects 0.000 claims description 4
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 4
- YMFPTJMPYCNHKO-ASXFNGKXSA-N 2-(1-adamantyl)-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=C2C=CN([C@@H](CO)C)C(=O)C2=CC=C1C YMFPTJMPYCNHKO-ASXFNGKXSA-N 0.000 claims description 3
- AYLWRSUFLVTPDR-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 AYLWRSUFLVTPDR-UHFFFAOYSA-N 0.000 claims description 3
- GVNUVQYGCQUSSM-OAHLLOKOSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2r)-1-(3-hydroxyazetidin-1-yl)propan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound C([C@@H](C)N1C(C2=CC=C(C)C(NC(=O)CC=3C=C(F)C(=CC=3)C(F)(F)F)=C2C=C1)=O)N1CC(O)C1 GVNUVQYGCQUSSM-OAHLLOKOSA-N 0.000 claims description 3
- JECILOFRRYCNDH-ZDUSSCGKSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[2-[(2s)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 JECILOFRRYCNDH-ZDUSSCGKSA-N 0.000 claims description 3
- CSYHHBNQBKHTNI-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-2-[2-(methylamino)ethyl]-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N(CCNC)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 CSYHHBNQBKHTNI-UHFFFAOYSA-N 0.000 claims description 3
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 3
- 208000001640 Fibromyalgia Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000004983 Phantom Limb Diseases 0.000 claims description 3
- 206010056238 Phantom pain Diseases 0.000 claims description 3
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 125000004947 alkyl aryl amino group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims description 3
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 3
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 3
- 239000007789 gas Substances 0.000 claims description 3
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 201000006370 kidney failure Diseases 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- 230000001953 sensory effect Effects 0.000 claims description 3
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 3
- NPYWIUPZYUTEAK-GFCCVEGCSA-N (2r)-2-[5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]propanamide Chemical compound CC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 NPYWIUPZYUTEAK-GFCCVEGCSA-N 0.000 claims description 2
- IXZKBFCFFLHLOH-CQSZACIVSA-N 2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxo-n-[[3-(trifluoromethyl)phenyl]methyl]isoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 IXZKBFCFFLHLOH-CQSZACIVSA-N 0.000 claims description 2
- OXONEBANLJOTOC-GFCCVEGCSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxo-n-[[2-(trifluoromethyl)phenyl]methyl]isoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=CC=C1C(F)(F)F OXONEBANLJOTOC-GFCCVEGCSA-N 0.000 claims description 2
- GBYDWBHRSCUQEX-GFCCVEGCSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxo-n-[[3-(trifluoromethyl)phenyl]methyl]isoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=CC(C(F)(F)F)=C1 GBYDWBHRSCUQEX-GFCCVEGCSA-N 0.000 claims description 2
- AGNFDSPQPAUSFK-LLVKDONJSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxo-n-[[6-(trifluoromethyl)pyridin-3-yl]methyl]isoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(C(F)(F)F)N=C1 AGNFDSPQPAUSFK-LLVKDONJSA-N 0.000 claims description 2
- STCKYUXIYJWHAM-SSDOTTSWSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxylic acid Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(O)=O STCKYUXIYJWHAM-SSDOTTSWSA-N 0.000 claims description 2
- YKSYAQQQDHLPJI-CQSZACIVSA-N 6-chloro-n-(cycloheptylmethyl)-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1CCCCCC1 YKSYAQQQDHLPJI-CQSZACIVSA-N 0.000 claims description 2
- PWBBZHNVXSPICS-LLVKDONJSA-N 6-chloro-n-[(4-chloro-3-fluorophenyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(Cl)C(F)=C1 PWBBZHNVXSPICS-LLVKDONJSA-N 0.000 claims description 2
- 208000001387 Causalgia Diseases 0.000 claims description 2
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 2
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims description 2
- 230000003412 degenerative effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- TWUJPPOAFORSHG-MRXNPFEDSA-N n-(cycloheptylmethyl)-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1CCCCCC1 TWUJPPOAFORSHG-MRXNPFEDSA-N 0.000 claims description 2
- KXQFFZDKVDPYRZ-MRXNPFEDSA-N n-[(1-hydroxycycloheptyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)CCCCCC1 KXQFFZDKVDPYRZ-MRXNPFEDSA-N 0.000 claims description 2
- BPPNPDKWLMZXDM-CYBMUJFWSA-N n-[(4-chloro-3-fluorophenyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinoline-5-carboxamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1=CC=C(Cl)C(F)=C1 BPPNPDKWLMZXDM-CYBMUJFWSA-N 0.000 claims description 2
- DUVRRTNJEKQIPG-UHFFFAOYSA-N n-[2-(1,3-dihydroxypropan-2-yl)-6-methyl-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C(C(N(C(CO)CO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 DUVRRTNJEKQIPG-UHFFFAOYSA-N 0.000 claims description 2
- UTMNVXYOFWISHC-CQSZACIVSA-N n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 UTMNVXYOFWISHC-CQSZACIVSA-N 0.000 claims description 2
- ITLBYFHASKQNFP-GFCCVEGCSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 ITLBYFHASKQNFP-GFCCVEGCSA-N 0.000 claims description 2
- XIGDTHFEXZYBMC-CQSZACIVSA-N n-[6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-cycloheptylacetamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1CCCCCC1 XIGDTHFEXZYBMC-CQSZACIVSA-N 0.000 claims description 2
- FMOOSLMLRAUSBH-NSHDSACASA-N n-[6-chloro-2-[(2s)-1-hydroxypropan-2-yl]-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound ClC1=CC=C2C(=O)N([C@H](CO)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 FMOOSLMLRAUSBH-NSHDSACASA-N 0.000 claims description 2
- 206010029240 Neuritis Diseases 0.000 claims 5
- 230000007794 irritation Effects 0.000 claims 4
- 208000018569 Respiratory Tract disease Diseases 0.000 claims 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 claims 2
- XUSXTHMTOSFZII-UHFFFAOYSA-N 1-(aminomethyl)cyclohexan-1-ol Chemical compound NCC1(O)CCCCC1 XUSXTHMTOSFZII-UHFFFAOYSA-N 0.000 claims 1
- AAMIKLACARMFCS-UHFFFAOYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]-n-[2-(2-hydroxyethyl)-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C(C(N(CCO)C=C2)=O)C2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 AAMIKLACARMFCS-UHFFFAOYSA-N 0.000 claims 1
- 206010003399 Arthropod bite Diseases 0.000 claims 1
- 206010006482 Bronchospasm Diseases 0.000 claims 1
- 206010008334 Cervicobrachial syndrome Diseases 0.000 claims 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 206010049949 Intercostal neuralgia Diseases 0.000 claims 1
- 208000007914 Labor Pain Diseases 0.000 claims 1
- 208000035945 Labour pain Diseases 0.000 claims 1
- 208000002472 Morton Neuroma Diseases 0.000 claims 1
- 208000020059 Morton neuralgia Diseases 0.000 claims 1
- 206010068106 Occipital neuralgia Diseases 0.000 claims 1
- 206010036105 Polyneuropathy Diseases 0.000 claims 1
- 208000008765 Sciatica Diseases 0.000 claims 1
- 208000003589 Spider Bites Diseases 0.000 claims 1
- 206010053509 Venomous bite Diseases 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 230000007885 bronchoconstriction Effects 0.000 claims 1
- 229960002504 capsaicin Drugs 0.000 claims 1
- 235000017663 capsaicin Nutrition 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000003127 knee Anatomy 0.000 claims 1
- 230000005906 menstruation Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 201000009985 neuronitis Diseases 0.000 claims 1
- 210000003254 palate Anatomy 0.000 claims 1
- 210000000578 peripheral nerve Anatomy 0.000 claims 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 claims 1
- 208000019629 polyneuritis Diseases 0.000 claims 1
- 239000003491 tear gas Substances 0.000 claims 1
- 210000001738 temporomandibular joint Anatomy 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 abstract description 6
- 208000026278 immune system disease Diseases 0.000 abstract description 5
- 229940124597 therapeutic agent Drugs 0.000 abstract description 5
- 230000002981 neuropathic effect Effects 0.000 abstract description 4
- 230000008736 traumatic injury Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 145
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 112
- 239000000203 mixture Substances 0.000 description 93
- 239000000047 product Substances 0.000 description 85
- 239000002904 solvent Substances 0.000 description 80
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 71
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 67
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 60
- 239000007787 solid Substances 0.000 description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 210000004027 cell Anatomy 0.000 description 58
- 229910052757 nitrogen Inorganic materials 0.000 description 51
- 238000003818 flash chromatography Methods 0.000 description 47
- 239000000243 solution Substances 0.000 description 44
- 125000001424 substituent group Chemical group 0.000 description 41
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 37
- 125000005843 halogen group Chemical group 0.000 description 35
- 230000002829 reductive effect Effects 0.000 description 35
- 238000012360 testing method Methods 0.000 description 34
- 102000005962 receptors Human genes 0.000 description 31
- 108020003175 receptors Proteins 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 30
- 241000700159 Rattus Species 0.000 description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 26
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 24
- 239000012071 phase Substances 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 23
- 125000004432 carbon atom Chemical group C* 0.000 description 23
- 150000002431 hydrogen Chemical class 0.000 description 23
- 230000002441 reversible effect Effects 0.000 description 23
- 125000005309 thioalkoxy group Chemical group 0.000 description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000003921 oil Substances 0.000 description 22
- 238000002953 preparative HPLC Methods 0.000 description 22
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 239000012267 brine Substances 0.000 description 20
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 20
- 229910000027 potassium carbonate Inorganic materials 0.000 description 19
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 17
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 16
- 125000005842 heteroatom Chemical group 0.000 description 15
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 15
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 238000009472 formulation Methods 0.000 description 14
- 229910052760 oxygen Inorganic materials 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 125000004423 acyloxy group Chemical group 0.000 description 13
- 229910052736 halogen Inorganic materials 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 239000003981 vehicle Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 12
- 235000019270 ammonium chloride Nutrition 0.000 description 12
- 150000002367 halogens Chemical class 0.000 description 12
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 125000005500 uronium group Chemical group 0.000 description 12
- 239000003039 volatile agent Substances 0.000 description 12
- AWJJLYZBWRIBCZ-UGTJMOTHSA-N 3'-O-(4-Benzoyl)benzoyl ATP Chemical compound O([C@@H]1[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]([C@@H]1O)N1C=2N=CN=C(C=2N=C1)N)C(=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 AWJJLYZBWRIBCZ-UGTJMOTHSA-N 0.000 description 11
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 11
- 125000004104 aryloxy group Chemical group 0.000 description 11
- 210000000269 carotid artery external Anatomy 0.000 description 11
- 229910052742 iron Inorganic materials 0.000 description 11
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 11
- RHRDOGKVOGSWKO-CYBMUJFWSA-N n-[2-[(2r)-1-azidopropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CN=[N+]=[N-])C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 RHRDOGKVOGSWKO-CYBMUJFWSA-N 0.000 description 11
- 229940090181 propyl acetate Drugs 0.000 description 11
- 125000005415 substituted alkoxy group Chemical group 0.000 description 11
- 125000005296 thioaryloxy group Chemical group 0.000 description 11
- 239000007995 HEPES buffer Substances 0.000 description 10
- 239000012981 Hank's balanced salt solution Substances 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 10
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 210000001616 monocyte Anatomy 0.000 description 10
- 125000005323 thioketone group Chemical group 0.000 description 10
- 229930194542 Keto Natural products 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- ULHRKLSNHXXJLO-UHFFFAOYSA-L Yo-Pro-1 Chemical compound [I-].[I-].C1=CC=C2C(C=C3N(C4=CC=CC=C4O3)C)=CC=[N+](CCC[N+](C)(C)C)C2=C1 ULHRKLSNHXXJLO-UHFFFAOYSA-L 0.000 description 9
- 239000000556 agonist Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000001072 colon Anatomy 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 125000000468 ketone group Chemical group 0.000 description 9
- 239000010410 layer Substances 0.000 description 9
- 229920006008 lipopolysaccharide Polymers 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 229920000728 polyester Polymers 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- OVOJUAKDTOOXRF-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O OVOJUAKDTOOXRF-UHFFFAOYSA-N 0.000 description 8
- 239000012980 RPMI-1640 medium Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 125000000392 cycloalkenyl group Chemical group 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 229960005322 streptomycin Drugs 0.000 description 8
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 7
- 229930182555 Penicillin Natural products 0.000 description 7
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 7
- CSYXMJDWYPPQIQ-SNVBAGLBSA-N [(2r)-2-(5-amino-6-methyl-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound CC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1N CSYXMJDWYPPQIQ-SNVBAGLBSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 239000000975 dye Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 229940049954 penicillin Drugs 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 7
- 229920000053 polysorbate 80 Polymers 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 125000003107 substituted aryl group Chemical group 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 7
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- KCYWNAAVPRMMLP-UHFFFAOYSA-N 5-nitroisochromen-1-one Chemical compound C1=COC(=O)C2=C1C([N+](=O)[O-])=CC=C2 KCYWNAAVPRMMLP-UHFFFAOYSA-N 0.000 description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 6
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 150000008064 anhydrides Chemical class 0.000 description 6
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 235000010418 carrageenan Nutrition 0.000 description 6
- 239000000679 carrageenan Substances 0.000 description 6
- 229920001525 carrageenan Polymers 0.000 description 6
- 229940113118 carrageenan Drugs 0.000 description 6
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 6
- 229960005542 ethidium bromide Drugs 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 6
- 125000001183 hydrocarbyl group Chemical group 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 6
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 5
- IGNIQYQEYLIVJD-UHFFFAOYSA-N 1-(aminomethyl)-4,4-dimethylcyclohexan-1-ol Chemical compound CC1(C)CCC(O)(CN)CC1 IGNIQYQEYLIVJD-UHFFFAOYSA-N 0.000 description 5
- ZFOWDXKJQNNLMW-UHFFFAOYSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 ZFOWDXKJQNNLMW-UHFFFAOYSA-N 0.000 description 5
- CWSFELCYANLRSG-UHFFFAOYSA-N 4,4-dimethyl-1-(nitromethyl)cyclohexan-1-ol Chemical compound CC1(C)CCC(O)(C[N+]([O-])=O)CC1 CWSFELCYANLRSG-UHFFFAOYSA-N 0.000 description 5
- YPRZJIMETXUVJU-CQSZACIVSA-N 6-chloro-n-[(1-hydroxy-4,4-dimethylcyclohexyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)CCC(C)(C)CC1 YPRZJIMETXUVJU-CQSZACIVSA-N 0.000 description 5
- 102000004506 Blood Proteins Human genes 0.000 description 5
- 108010017384 Blood Proteins Proteins 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- XWVYLTQUMPLTJS-MRVPVSSYSA-N [(2r)-2-(5-amino-6-chloro-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1N XWVYLTQUMPLTJS-MRVPVSSYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 150000001768 cations Chemical class 0.000 description 5
- 201000002491 encephalomyelitis Diseases 0.000 description 5
- 210000002683 foot Anatomy 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 125000002950 monocyclic group Chemical group 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 229920006395 saturated elastomer Polymers 0.000 description 5
- 210000003497 sciatic nerve Anatomy 0.000 description 5
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical compound C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 208000004454 Hyperalgesia Diseases 0.000 description 4
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 4
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- 229910052777 Praseodymium Inorganic materials 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- WAWJJGACRTUZKD-MRVPVSSYSA-N [(2r)-2-(6-chloro-5-iodo-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1I WAWJJGACRTUZKD-MRVPVSSYSA-N 0.000 description 4
- LZWFQHJWCGQNPT-CYBMUJFWSA-N [(2r)-2-[6-chloro-5-[(4,4-difluorocyclohexyl)methylcarbamoyl]-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1C(=O)NCC1CCC(F)(F)CC1 LZWFQHJWCGQNPT-CYBMUJFWSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 125000005907 alkyl ester group Chemical group 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 210000004004 carotid artery internal Anatomy 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 210000000548 hind-foot Anatomy 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000011630 iodine Substances 0.000 description 4
- 125000002346 iodo group Chemical group I* 0.000 description 4
- 229960002725 isoflurane Drugs 0.000 description 4
- 210000002414 leg Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 201000001119 neuropathy Diseases 0.000 description 4
- 230000007823 neuropathy Effects 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 4
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- 230000002285 radioactive effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000010189 synthetic method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 208000009935 visceral pain Diseases 0.000 description 4
- VVRVZXIIKFLHIH-NRYLJRBGSA-N (2r)-2-aminopropan-1-ol Chemical compound C[C@@H](N)CO.C[C@@H](N)CO VVRVZXIIKFLHIH-NRYLJRBGSA-N 0.000 description 3
- QXOGPTXQGKQSJT-UHFFFAOYSA-N 1-amino-4-[4-(3,4-dimethylphenyl)sulfanylanilino]-9,10-dioxoanthracene-2-sulfonic acid Chemical compound Cc1ccc(Sc2ccc(Nc3cc(c(N)c4C(=O)c5ccccc5C(=O)c34)S(O)(=O)=O)cc2)cc1C QXOGPTXQGKQSJT-UHFFFAOYSA-N 0.000 description 3
- MLORHOHNTRJWCX-MRVPVSSYSA-N 2-[(2r)-1-hydroxypropan-2-yl]-5-nitroisoquinolin-1-one Chemical compound C1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1[N+]([O-])=O MLORHOHNTRJWCX-MRVPVSSYSA-N 0.000 description 3
- LMPORRRHHAJHIG-SECBINFHSA-N 2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-5-nitroisoquinolin-1-one Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1[N+]([O-])=O LMPORRRHHAJHIG-SECBINFHSA-N 0.000 description 3
- RJHUDVUVZDMYPZ-UHFFFAOYSA-N 6-chloro-5-nitroisochromen-1-one Chemical compound C1=COC(=O)C2=C1C([N+](=O)[O-])=C(Cl)C=C2 RJHUDVUVZDMYPZ-UHFFFAOYSA-N 0.000 description 3
- MQTSSHSNQCUTBQ-UHFFFAOYSA-N 6-methyl-5-nitroisochromen-1-one Chemical compound C1=COC(=O)C=2C1=C([N+]([O-])=O)C(C)=CC=2 MQTSSHSNQCUTBQ-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108091006146 Channels Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- 206010033799 Paralysis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- ZNZVHQMITHAORJ-SNVBAGLBSA-N [(2r)-2-(6-methyl-5-nitro-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound CC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1[N+]([O-])=O ZNZVHQMITHAORJ-SNVBAGLBSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 230000001363 autoimmune Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthene Chemical compound C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000004731 jugular vein Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- JBXLGRYXUPBUFC-BQYQJAHWSA-N methyl 2-[(e)-2-(dimethylamino)ethenyl]-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1\C=C\N(C)C JBXLGRYXUPBUFC-BQYQJAHWSA-N 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000008823 permeabilization Effects 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 235000010288 sodium nitrite Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 125000005017 substituted alkenyl group Chemical group 0.000 description 3
- 125000004426 substituted alkynyl group Chemical group 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 229930192474 thiophene Natural products 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- JYXDRZYJCKNSIK-SSDOTTSWSA-N (2r)-2-(5-amino-6-methoxy-1-oxoisoquinolin-2-yl)propanamide Chemical compound C1=CN([C@H](C)C(N)=O)C(=O)C=2C1=C(N)C(OC)=CC=2 JYXDRZYJCKNSIK-SSDOTTSWSA-N 0.000 description 2
- ZDNPYAOMVCEUKL-IGMKFADOSA-N (2r)-2-[5-[[2-(2-adamantyl)acetyl]amino]-6-chloro-1-oxoisoquinolin-2-yl]propanamide Chemical compound C1C(CC2C3)CC3CC1C2CC(=O)NC1=C2C=CN([C@@H](C(N)=O)C)C(=O)C2=CC=C1Cl ZDNPYAOMVCEUKL-IGMKFADOSA-N 0.000 description 2
- GITOYMUZGBNOSS-LURJTMIESA-N (2s)-2-(5-amino-6-chloro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1N GITOYMUZGBNOSS-LURJTMIESA-N 0.000 description 2
- OQANPHBRHBJGNZ-FYJGNVAPSA-N (3e)-6-oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid Chemical compound C1=CC(=O)C(C(=O)O)=C\C1=N\NC1=CC=C(S(=O)(=O)NC=2N=CC=CC=2)C=C1 OQANPHBRHBJGNZ-FYJGNVAPSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 2
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 2
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 2
- GWGBNENHEGYJSN-UHFFFAOYSA-N 2,4-dinitrobenzenesulfonic acid;hydrate Chemical compound O.OS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O GWGBNENHEGYJSN-UHFFFAOYSA-N 0.000 description 2
- DUTSFJNGJCYOFL-UHFFFAOYSA-N 2-(5-amino-6-chloro-1-oxoisoquinolin-2-yl)ethyl acetate Chemical compound ClC1=CC=C2C(=O)N(CCOC(=O)C)C=CC2=C1N DUTSFJNGJCYOFL-UHFFFAOYSA-N 0.000 description 2
- HNORVZDAANCHAY-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(C(F)(F)F)C=C1 HNORVZDAANCHAY-UHFFFAOYSA-N 0.000 description 2
- FYBFXTQENXYJPL-UHFFFAOYSA-N 2-[6-chloro-5-[[2-[4-fluoro-3-(trifluoromethyl)phenyl]acetyl]amino]-1-oxoisoquinolin-2-yl]ethyl acetate Chemical compound ClC1=CC=C2C(=O)N(CCOC(=O)C)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 FYBFXTQENXYJPL-UHFFFAOYSA-N 0.000 description 2
- VIBPXYKZBZGMNK-UHFFFAOYSA-N 2-[[2-(2-acetyloxyethyl)-5-[[2-[2-fluoro-3-(trifluoromethyl)phenyl]acetyl]amino]-1-oxoisoquinolin-6-yl]amino]ethyl acetate Chemical compound CC(=O)OCCNC1=CC=C(C(N(CCOC(C)=O)C=C2)=O)C2=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1F VIBPXYKZBZGMNK-UHFFFAOYSA-N 0.000 description 2
- PXSTWENPKBZQJH-UHFFFAOYSA-N 2-[[2-(2-acetyloxyethyl)-5-nitro-1-oxoisoquinolin-6-yl]amino]ethyl acetate Chemical compound C1=CN(CCOC(C)=O)C(=O)C=2C1=C([N+]([O-])=O)C(NCCOC(=O)C)=CC=2 PXSTWENPKBZQJH-UHFFFAOYSA-N 0.000 description 2
- UXGVMFHEKMGWMA-UHFFFAOYSA-N 2-benzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 2
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 2
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 2
- LRBGMTZLMIMKLP-UHFFFAOYSA-N 4-chloro-2-methyl-3-nitrobenzoic acid Chemical compound CC1=C(C(O)=O)C=CC(Cl)=C1[N+]([O-])=O LRBGMTZLMIMKLP-UHFFFAOYSA-N 0.000 description 2
- OFELFQJDRMOISA-UHFFFAOYSA-N 5-aminoisochromen-1-one Chemical compound C1=COC(=O)C2=C1C(N)=CC=C2 OFELFQJDRMOISA-UHFFFAOYSA-N 0.000 description 2
- GMDPUTAUKHHDCI-UHFFFAOYSA-N 5-nitro-2h-isoquinolin-1-one Chemical class C1=CNC(=O)C2=C1C([N+](=O)[O-])=CC=C2 GMDPUTAUKHHDCI-UHFFFAOYSA-N 0.000 description 2
- GREXEAVVIKEANB-UHFFFAOYSA-N 6-bromo-5-nitroisochromen-1-one Chemical compound C1=COC(=O)C2=C1C([N+](=O)[O-])=C(Br)C=C2 GREXEAVVIKEANB-UHFFFAOYSA-N 0.000 description 2
- UJZSPURKVKETKB-UHFFFAOYSA-N 6-cyclopropyl-5-nitroisochromen-1-one Chemical compound C1=CC(C(OC=C2)=O)=C2C([N+](=O)[O-])=C1C1CC1 UJZSPURKVKETKB-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 2
- 244000146493 Cryptotaenia japonica Species 0.000 description 2
- 235000004035 Cryptotaenia japonica Nutrition 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- 208000009386 Experimental Arthritis Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical group NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
- 206010033645 Pancreatitis Diseases 0.000 description 2
- 108010081690 Pertussis Toxin Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 229910001115 Zinc-copper couple Inorganic materials 0.000 description 2
- WZFQVPBLGBGXSN-SECBINFHSA-N [(2r)-2-(5-amino-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound C1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1N WZFQVPBLGBGXSN-SECBINFHSA-N 0.000 description 2
- PXVGPYRTNSETIM-SNVBAGLBSA-N [(2r)-2-(5-amino-6-cyclopropyl-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound C=1C=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C(N)C=1C1CC1 PXVGPYRTNSETIM-SNVBAGLBSA-N 0.000 description 2
- QMRQUQAKSACNBL-SECBINFHSA-N [(2r)-2-(5-nitro-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound C1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1[N+]([O-])=O QMRQUQAKSACNBL-SECBINFHSA-N 0.000 description 2
- YREIDVFAYSARAO-QGZVFWFLSA-N [(2r)-2-[5-[(2-cycloheptylacetyl)amino]-6-methyl-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound CC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1NC(=O)CC1CCCCCC1 YREIDVFAYSARAO-QGZVFWFLSA-N 0.000 description 2
- FXHCNXOJAWJPCD-KMOWTAILSA-N [(2r)-2-[5-[[2-(1-adamantyl)acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=C2C=CN([C@@H](COC(C)=O)C)C(=O)C2=CC=C1C FXHCNXOJAWJPCD-KMOWTAILSA-N 0.000 description 2
- BTKYXYUMIRPDSF-QGZVFWFLSA-N [(2r)-2-[5-[[2-(1-hydroxycycloheptyl)acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound CC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1NC(=O)CC1(O)CCCCCC1 BTKYXYUMIRPDSF-QGZVFWFLSA-N 0.000 description 2
- OZNWSPXRSIWRAQ-CQSZACIVSA-N [(2r)-2-[5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]propyl] methanesulfonate Chemical compound CC1=CC=C2C(=O)N([C@@H](COS(C)(=O)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 OZNWSPXRSIWRAQ-CQSZACIVSA-N 0.000 description 2
- ISIUSOBCSGSFHL-GFCCVEGCSA-N [(2r)-2-[6-chloro-5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 ISIUSOBCSGSFHL-GFCCVEGCSA-N 0.000 description 2
- GAWATKIQLFHZJT-GFCCVEGCSA-N [(2r)-2-[6-chloro-5-[[3-fluoro-4-(trifluoromethyl)phenyl]methylcarbamoyl]-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1C(=O)NCC1=CC=C(C(F)(F)F)C(F)=C1 GAWATKIQLFHZJT-GFCCVEGCSA-N 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 230000001594 aberrant effect Effects 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 2
- WDECIBYCCFPHNR-UHFFFAOYSA-N chrysene Chemical compound C1=CC=CC2=CC=C3C4=CC=CC=C4C=CC3=C21 WDECIBYCCFPHNR-UHFFFAOYSA-N 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 2
- VPUGDVKSAQVFFS-UHFFFAOYSA-N coronene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3)C4=C4C3=CC=C(C=C3)C4=C2C3=C1 VPUGDVKSAQVFFS-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000014793 distal colitis Diseases 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 2
- NEXSMEBSBIABKL-UHFFFAOYSA-N hexamethyldisilane Chemical compound C[Si](C)(C)[Si](C)(C)C NEXSMEBSBIABKL-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical compound C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 2
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000011670 long-evans rat Methods 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- OBEIQHRWPFVXDA-UHFFFAOYSA-N methyl 4-chloro-2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1C OBEIQHRWPFVXDA-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 108010064578 myelin proteolipid protein (139-151) Proteins 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- GBROPGWFBFCKAG-UHFFFAOYSA-N picene Chemical compound C1=CC2=C3C=CC=CC3=CC=C2C2=C1C1=CC=CC=C1C=C2 GBROPGWFBFCKAG-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 description 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 229940044601 receptor agonist Drugs 0.000 description 2
- 239000000018 receptor agonist Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000008790 seltzer Nutrition 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- PXIGSUWVCSOFMF-UHFFFAOYSA-N spiro[2.5]octan-6-one Chemical compound C1CC(=O)CCC11CC1 PXIGSUWVCSOFMF-UHFFFAOYSA-N 0.000 description 2
- 238000013222 sprague-dawley male rat Methods 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 210000000966 temporal muscle Anatomy 0.000 description 2
- MLOFPRVIDVHTPK-ZDUSSCGKSA-N tert-butyl (3s)-3-(5-amino-6-methyl-1-oxoisoquinolin-2-yl)pyrrolidine-1-carboxylate Chemical compound NC=1C(C)=CC=C(C2=O)C=1C=CN2[C@H]1CCN(C(=O)OC(C)(C)C)C1 MLOFPRVIDVHTPK-ZDUSSCGKSA-N 0.000 description 2
- NSOYLFGJKXZCBX-UHFFFAOYSA-N tert-butyl n-[2-(5-amino-6-methyl-1-oxoisoquinolin-2-yl)ethyl]-n-methylcarbamate Chemical compound CC1=CC=C2C(=O)N(CCN(C)C(=O)OC(C)(C)C)C=CC2=C1N NSOYLFGJKXZCBX-UHFFFAOYSA-N 0.000 description 2
- DYSSZMWDDSOADG-UHFFFAOYSA-N tert-butyl n-[2-[5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]ethyl]-n-methylcarbamate Chemical compound CC1=CC=C2C(=O)N(CCN(C)C(=O)OC(C)(C)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 DYSSZMWDDSOADG-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical class 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 2
- 150000003852 triazoles Chemical class 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical group OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- AIFRHYZBTHREPW-UHFFFAOYSA-N β-carboline Chemical compound N1=CC=C2C3=CC=CC=C3NC2=C1 AIFRHYZBTHREPW-UHFFFAOYSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- GITOYMUZGBNOSS-ZCFIWIBFSA-N (2r)-2-(5-amino-6-chloro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1N GITOYMUZGBNOSS-ZCFIWIBFSA-N 0.000 description 1
- WNUCRXXBFRWADY-ZCFIWIBFSA-N (2r)-2-(6-chloro-5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](C(N)=O)C)C=CC2=C1[N+]([O-])=O WNUCRXXBFRWADY-ZCFIWIBFSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- WNUCRXXBFRWADY-LURJTMIESA-N (2s)-2-(6-chloro-5-nitro-1-oxoisoquinolin-2-yl)propanamide Chemical compound ClC1=CC=C2C(=O)N([C@H](C(N)=O)C)C=CC2=C1[N+]([O-])=O WNUCRXXBFRWADY-LURJTMIESA-N 0.000 description 1
- UXUFTKZYJYGMGO-CMCWBKRRSA-N (2s,3s,4r,5r)-5-[6-amino-2-[2-[4-[3-(2-aminoethylamino)-3-oxopropyl]phenyl]ethylamino]purin-9-yl]-n-ethyl-3,4-dihydroxyoxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(=O)NCCN)=CC=3)=NC(N)=C2N=C1 UXUFTKZYJYGMGO-CMCWBKRRSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 description 1
- HNJQCPHETXMWSG-UHFFFAOYSA-N (4,4-difluorocyclohexyl)methanamine;hydrochloride Chemical compound Cl.NCC1CCC(F)(F)CC1 HNJQCPHETXMWSG-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical compound C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- AAQTWLBJPNLKHT-UHFFFAOYSA-N 1H-perimidine Chemical compound N1C=NC2=CC=CC3=CC=CC1=C32 AAQTWLBJPNLKHT-UHFFFAOYSA-N 0.000 description 1
- JAAGHUBILRENEC-UHFFFAOYSA-N 1h-benzo[g]indazole Chemical compound C1=CC2=CC=CC=C2C2=C1C=NN2 JAAGHUBILRENEC-UHFFFAOYSA-N 0.000 description 1
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- AOTQGWFNFTVXNQ-UHFFFAOYSA-N 2-(1-adamantyl)acetic acid Chemical compound C1C(C2)CC3CC2CC1(CC(=O)O)C3 AOTQGWFNFTVXNQ-UHFFFAOYSA-N 0.000 description 1
- YZSDRLDFJDIPDA-MRXNPFEDSA-N 2-(1-hydroxycycloheptyl)-n-[2-[(2r)-1-hydroxypropan-2-yl]-6-methyl-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1NC(=O)CC1(O)CCCCCC1 YZSDRLDFJDIPDA-MRXNPFEDSA-N 0.000 description 1
- BUWXYMMPKVJGKZ-UHFFFAOYSA-N 2-(1-hydroxycycloheptyl)acetic acid Chemical compound OC(=O)CC1(O)CCCCCC1 BUWXYMMPKVJGKZ-UHFFFAOYSA-N 0.000 description 1
- NGLXYIKMPIMIJB-UHFFFAOYSA-N 2-(2-hydroxyethyl)-6-(2-hydroxyethylamino)-5-nitroisoquinolin-1-one Chemical compound C1=CN(CCO)C(=O)C=2C1=C([N+]([O-])=O)C(NCCO)=CC=2 NGLXYIKMPIMIJB-UHFFFAOYSA-N 0.000 description 1
- YWKBUICTNQUBEV-UHFFFAOYSA-N 2-(6-chloro-5-nitro-1-oxoisoquinolin-2-yl)ethyl acetate Chemical compound ClC1=CC=C2C(=O)N(CCOC(=O)C)C=CC2=C1[N+]([O-])=O YWKBUICTNQUBEV-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- IZXLNEHPKQVCAE-UHFFFAOYSA-N 2-[2-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1F IZXLNEHPKQVCAE-UHFFFAOYSA-N 0.000 description 1
- AQWBOPTZKNLNOV-QGZVFWFLSA-N 2-[3-fluoro-4-(trifluoromethyl)phenyl]-n-[6-methyl-2-[(2r)-1-[methyl(prop-2-enyl)amino]propan-2-yl]-1-oxoisoquinolin-5-yl]acetamide Chemical compound CC1=CC=C2C(=O)N([C@@H](CN(C)CC=C)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 AQWBOPTZKNLNOV-QGZVFWFLSA-N 0.000 description 1
- MGQPQAYFSXCYPW-UHFFFAOYSA-N 2-[4-fluoro-3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 MGQPQAYFSXCYPW-UHFFFAOYSA-N 0.000 description 1
- FXVWYAXIWINTHT-UHFFFAOYSA-N 2-[[2-(2-acetyloxyethyl)-5-amino-1-oxoisoquinolin-6-yl]amino]ethyl acetate Chemical compound C1=CN(CCOC(C)=O)C(=O)C=2C1=C(N)C(NCCOC(=O)C)=CC=2 FXVWYAXIWINTHT-UHFFFAOYSA-N 0.000 description 1
- LNHILYINDTUUMZ-UHFFFAOYSA-N 2-[carboxymethyl(9h-fluoren-9-ylmethoxycarbonyl)amino]acetic acid Chemical compound C1=CC=C2C(COC(=O)N(CC(O)=O)CC(=O)O)C3=CC=CC=C3C2=C1 LNHILYINDTUUMZ-UHFFFAOYSA-N 0.000 description 1
- KDZPPKQYVFWGGV-UHFFFAOYSA-N 2-aminoisoquinolin-1-one Chemical class C1=CC=C2C(=O)N(N)C=CC2=C1 KDZPPKQYVFWGGV-UHFFFAOYSA-N 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N 3,3-dimethylbutyric acid Chemical compound CC(C)(C)CC(O)=O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- XLZYKTYMLBOINK-UHFFFAOYSA-N 3-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(C(=O)C=2C=CC(O)=CC=2)=C1 XLZYKTYMLBOINK-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- USXDKZHAWAGQNA-UHFFFAOYSA-N 3-nitroisochromen-1-one Chemical compound C1=CC=C2C(=O)OC([N+](=O)[O-])=CC2=C1 USXDKZHAWAGQNA-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- PXQMSTLNSHMSJB-UHFFFAOYSA-N 4,4-dimethylcyclohexan-1-one Chemical compound CC1(C)CCC(=O)CC1 PXQMSTLNSHMSJB-UHFFFAOYSA-N 0.000 description 1
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1h-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 1
- XXFKOBGFMUIWDH-UHFFFAOYSA-N 4-chloro-2-methylbenzoic acid Chemical compound CC1=CC(Cl)=CC=C1C(O)=O XXFKOBGFMUIWDH-UHFFFAOYSA-N 0.000 description 1
- QJNLUNBGDFUULX-UHFFFAOYSA-N 4-n,4-n'-dimethyl-3h-pyridine-4,4-diamine Chemical compound CNC1(NC)CC=NC=C1 QJNLUNBGDFUULX-UHFFFAOYSA-N 0.000 description 1
- LAOZSCRCYVBSJA-UHFFFAOYSA-N 5,5-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound CC1(C)C(=O)NC(=O)NC1=O LAOZSCRCYVBSJA-UHFFFAOYSA-N 0.000 description 1
- FLDSMVTWEZKONL-AWEZNQCLSA-N 5,5-dimethyl-N-[(3S)-5-methyl-4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-1,4,7,8-tetrahydrooxepino[4,5-c]pyrazole-3-carboxamide Chemical compound CC1(CC2=C(NN=C2C(=O)N[C@@H]2C(N(C3=C(OC2)C=CC=C3)C)=O)CCO1)C FLDSMVTWEZKONL-AWEZNQCLSA-N 0.000 description 1
- SVASVGVAQIVSEZ-UHFFFAOYSA-N 5-amino-2H-isoquinolin-1-one Chemical class C1=CNC(=O)C2=C1C(N)=CC=C2 SVASVGVAQIVSEZ-UHFFFAOYSA-N 0.000 description 1
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 1
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 1
- RBFCYHXQQVWFDS-UHFFFAOYSA-N 6-(aminomethyl)spiro[2.5]octan-6-ol;hydrochloride Chemical compound Cl.C1CC(CN)(O)CCC11CC1 RBFCYHXQQVWFDS-UHFFFAOYSA-N 0.000 description 1
- ZVWTXHJYNMSMKO-UHFFFAOYSA-N 6-(nitromethyl)spiro[2.5]octan-6-ol Chemical compound C1CC(O)(C[N+]([O-])=O)CCC11CC1 ZVWTXHJYNMSMKO-UHFFFAOYSA-N 0.000 description 1
- WAVJTIBLOFDVEO-UHFFFAOYSA-N 6-chloro-2-(2-hydroxyethyl)-5-nitroisoquinolin-1-one Chemical compound ClC1=CC=C2C(=O)N(CCO)C=CC2=C1[N+]([O-])=O WAVJTIBLOFDVEO-UHFFFAOYSA-N 0.000 description 1
- SJAVUAZUMAXZHV-SSDOTTSWSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-5-nitroisoquinolin-1-one Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1[N+]([O-])=O SJAVUAZUMAXZHV-SSDOTTSWSA-N 0.000 description 1
- LUWYOKHBDDGNHP-CQSZACIVSA-N 6-chloro-2-[(2r)-1-hydroxypropan-2-yl]-n-[(6-hydroxyspiro[2.5]octan-6-yl)methyl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC(CC1)(O)CCC21CC2 LUWYOKHBDDGNHP-CQSZACIVSA-N 0.000 description 1
- FHXZVDBITWXWNE-CYBMUJFWSA-N 6-chloro-n-[(1-hydroxycyclohexyl)methyl]-2-[(2r)-1-hydroxypropan-2-yl]-1-oxoisoquinoline-5-carboxamide Chemical compound ClC1=CC=C2C(=O)N([C@@H](CO)C)C=CC2=C1C(=O)NCC1(O)CCCCC1 FHXZVDBITWXWNE-CYBMUJFWSA-N 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- BCWKBPCNPHCCQS-UHFFFAOYSA-N 8-methylidene-1,4-dioxaspiro[4.5]decane Chemical compound C1CC(=C)CCC21OCCO2 BCWKBPCNPHCCQS-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- QGZKDVFQNNGYKY-OUBTZVSYSA-N Ammonia-15N Chemical compound [15NH3] QGZKDVFQNNGYKY-OUBTZVSYSA-N 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 238000011731 BALB/cByJ (JAX™ mouse strain) Methods 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- ISMDILRWKSYCOD-GNKBHMEESA-N C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O Chemical compound C(C1=CC=CC=C1)[C@@H]1NC(OCCCCCCCCCCCNC([C@@H](NC(C[C@@H]1O)=O)C(C)C)=O)=O ISMDILRWKSYCOD-GNKBHMEESA-N 0.000 description 1
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- PCBZRNYXXCIELG-WYFCWLEVSA-N COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 Chemical compound COC1=CC=C(C[C@H](NC(=O)OC2CCCC3(C2)OOC2(O3)C3CC4CC(C3)CC2C4)C(=O)N[C@@H]2[C@@H](CO)O[C@H]([C@@H]2O)N2C=NC3=C2N=CN=C3N(C)C)C=C1 PCBZRNYXXCIELG-WYFCWLEVSA-N 0.000 description 1
- 238000003650 Calcium Assay Kit Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010061819 Disease recurrence Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101001098175 Homo sapiens P2X purinoceptor 7 Proteins 0.000 description 1
- 101001047090 Homo sapiens Potassium voltage-gated channel subfamily H member 2 Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241001049988 Mycobacterium tuberculosis H37Ra Species 0.000 description 1
- 102000055324 Myelin Proteolipid Human genes 0.000 description 1
- 101710094913 Myelin proteolipid protein Proteins 0.000 description 1
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 239000006057 Non-nutritive feed additive Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091075598 P2X receptor family Proteins 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLGBZMMZGDRARJ-UHFFFAOYSA-N Triphenylene Natural products C1=CC=C2C3=CC=CC=C3C3=CC=CC=C3C2=C1 SLGBZMMZGDRARJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- IOSLINNLJFQMFF-XMMPIXPASA-N [(2R)-1-[[4-[[3-[(4-fluorophenyl)methylsulfanyl]phenoxy]methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound FC1=CC=C(CSC=2C=C(OCC3=CC=C(CN4[C@H](CCC4)CO)C=C3)C=CC=2)C=C1 IOSLINNLJFQMFF-XMMPIXPASA-N 0.000 description 1
- HKUHAOBETUXXDQ-MRVPVSSYSA-N [(2r)-2-(6-chloro-5-nitro-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1[N+]([O-])=O HKUHAOBETUXXDQ-MRVPVSSYSA-N 0.000 description 1
- JFXZBYVIDYWWBB-SNVBAGLBSA-N [(2r)-2-(6-cyclopropyl-5-nitro-1-oxoisoquinolin-2-yl)propyl] acetate Chemical compound C=1C=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C([N+]([O-])=O)C=1C1CC1 JFXZBYVIDYWWBB-SNVBAGLBSA-N 0.000 description 1
- QEQPNTNKUUTQEZ-CQSZACIVSA-N [(2r)-2-[5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound CC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 QEQPNTNKUUTQEZ-CQSZACIVSA-N 0.000 description 1
- NHNUKCRHEBYKRL-OAHLLOKOSA-N [(2r)-2-[6-chloro-5-[(1-hydroxycycloheptyl)methylcarbamoyl]-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1C(=O)NCC1(O)CCCCCC1 NHNUKCRHEBYKRL-OAHLLOKOSA-N 0.000 description 1
- VYYNMICMDYSGCP-GFCCVEGCSA-N [(2r)-2-[6-chloro-5-[[2-[4-fluoro-3-(trifluoromethyl)phenyl]acetyl]amino]-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound ClC1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1NC(=O)CC1=CC=C(F)C(C(F)(F)F)=C1 VYYNMICMDYSGCP-GFCCVEGCSA-N 0.000 description 1
- NRXXPAPRZSBMSE-CQSZACIVSA-N [(2r)-2-[6-cyclopropyl-5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-1-oxoisoquinolin-2-yl]propyl] acetate Chemical compound C1CC1C1=CC=C2C(=O)N([C@@H](COC(C)=O)C)C=CC2=C1NC(=O)CC1=CC=C(C(F)(F)F)C(F)=C1 NRXXPAPRZSBMSE-CQSZACIVSA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- FIAINKIUSZGVGX-DKWTVANSSA-N [(2s)-1-amino-1-oxopropan-2-yl]azanium;chloride Chemical compound Cl.C[C@H](N)C(N)=O FIAINKIUSZGVGX-DKWTVANSSA-N 0.000 description 1
- QVXFGVVYTKZLJN-KHPPLWFESA-N [(z)-hexadec-7-enyl] acetate Chemical compound CCCCCCCC\C=C/CCCCCCOC(C)=O QVXFGVVYTKZLJN-KHPPLWFESA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- XYWYEOHNURYGGP-UHFFFAOYSA-N [3-fluoro-4-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(C(F)(F)F)C(F)=C1 XYWYEOHNURYGGP-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 125000004054 acenaphthylenyl group Chemical group C1(=CC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- SQFPKRNUGBRTAR-UHFFFAOYSA-N acephenanthrylene Chemical group C1=CC(C=C2)=C3C2=CC2=CC=CC=C2C3=C1 SQFPKRNUGBRTAR-UHFFFAOYSA-N 0.000 description 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- HXGDTGSAIMULJN-UHFFFAOYSA-N acetnaphthylene Natural products C1=CC(C=C2)=C3C2=CC=CC3=C1 HXGDTGSAIMULJN-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical class C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229960002648 alanylglutamine Drugs 0.000 description 1
- GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000002009 alkene group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000000033 alkoxyamino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 1
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003994 anesthetic gas Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- BVUSIQTYUVWOSX-UHFFFAOYSA-N arsindole Chemical compound C1=CC=C2[As]C=CC2=C1 BVUSIQTYUVWOSX-UHFFFAOYSA-N 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- KNNXFYIMEYKHBZ-UHFFFAOYSA-N as-indacene Chemical compound C1=CC2=CC=CC2=C2C=CC=C21 KNNXFYIMEYKHBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- AAMATCKFMHVIDO-UHFFFAOYSA-N azane;1h-pyrrole Chemical compound N.C=1C=CNC=1 AAMATCKFMHVIDO-UHFFFAOYSA-N 0.000 description 1
- UQUPQEUNHVVNKW-UHFFFAOYSA-N azetidin-1-ium-3-ol;chloride Chemical compound Cl.OC1CNC1 UQUPQEUNHVVNKW-UHFFFAOYSA-N 0.000 description 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- DPECLNSLLIQJJO-UHFFFAOYSA-M benzyl-diethyl-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethyl]azanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1C[N+](CC)(CC)CCOC1=CC=C(C(C)(C)CC(C)(C)C)C=C1 DPECLNSLLIQJJO-UHFFFAOYSA-M 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical group [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000004112 carboxyamino group Chemical group [H]OC(=O)N([H])[*] 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940126545 compound 53 Drugs 0.000 description 1
- 229940125900 compound 59 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
- 125000006622 cycloheptylmethyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000006623 cyclooctylmethyl group Chemical group 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- VRRJYERADSBBPI-JIZZDEOASA-L dicesium;(2s)-2-aminobutanedioate Chemical compound [Cs+].[Cs+].[O-]C(=O)[C@@H](N)CC([O-])=O VRRJYERADSBBPI-JIZZDEOASA-L 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940052761 dopaminergic adamantane derivative Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 150000002085 enols Chemical class 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- RMBPEFMHABBEKP-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2C3=C[CH]C=CC3=CC2=C1 RMBPEFMHABBEKP-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002244 furazanes Chemical class 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 230000003370 grooming effect Effects 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical group CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- QSQIGGCOCHABAP-UHFFFAOYSA-N hexacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC=CC=C6C=C5C=C4C=C3C=C21 QSQIGGCOCHABAP-UHFFFAOYSA-N 0.000 description 1
- PKIFBGYEEVFWTJ-UHFFFAOYSA-N hexaphene Chemical compound C1=CC=C2C=C3C4=CC5=CC6=CC=CC=C6C=C5C=C4C=CC3=CC2=C1 PKIFBGYEEVFWTJ-UHFFFAOYSA-N 0.000 description 1
- 208000010726 hind limb paralysis Diseases 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 239000008309 hydrophilic cream Substances 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- CRZGFIMLHZTLGT-UHFFFAOYSA-N methyl 2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=CC([N+]([O-])=O)=C1C CRZGFIMLHZTLGT-UHFFFAOYSA-N 0.000 description 1
- SFOUMZZLBCFDEN-UHFFFAOYSA-N methyl 4-bromo-2-methyl-3-nitrobenzoate Chemical compound COC(=O)C1=CC=C(Br)C([N+]([O-])=O)=C1C SFOUMZZLBCFDEN-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 229940050176 methyl chloride Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- LSEFCHWGJNHZNT-UHFFFAOYSA-M methyl(triphenyl)phosphanium;bromide Chemical compound [Br-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(C)C1=CC=CC=C1 LSEFCHWGJNHZNT-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- YCJZWBZJSYLMPB-UHFFFAOYSA-N n-(2-chloropyrimidin-4-yl)-2,5-dimethyl-1-phenylimidazole-4-carboxamide Chemical compound CC=1N(C=2C=CC=CC=2)C(C)=NC=1C(=O)NC1=CC=NC(Cl)=N1 YCJZWBZJSYLMPB-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- IOXXVNYDGIXMIP-UHFFFAOYSA-N n-methylprop-2-en-1-amine Chemical compound CNCC=C IOXXVNYDGIXMIP-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000007971 neurological deficit Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- HKKDKUMUWRTAIA-UHFFFAOYSA-N nitridooxidocarbon(.) Chemical compound [O]C#N HKKDKUMUWRTAIA-UHFFFAOYSA-N 0.000 description 1
- VLZLOWPYUQHHCG-UHFFFAOYSA-N nitromethylbenzene Chemical compound [O-][N+](=O)CC1=CC=CC=C1 VLZLOWPYUQHHCG-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N o-biphenylenemethane Natural products C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 description 1
- PFTXKXWAXWAZBP-UHFFFAOYSA-N octacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC6=CC7=CC8=CC=CC=C8C=C7C=C6C=C5C=C4C=C3C=C21 PFTXKXWAXWAZBP-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- OVPVGJFDFSJUIG-UHFFFAOYSA-N octalene Chemical compound C1=CC=CC=C2C=CC=CC=CC2=C1 OVPVGJFDFSJUIG-UHFFFAOYSA-N 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- LSQODMMMSXHVCN-UHFFFAOYSA-N ovalene Chemical compound C1=C(C2=C34)C=CC3=CC=C(C=C3C5=C6C(C=C3)=CC=C3C6=C6C(C=C3)=C3)C4=C5C6=C2C3=C1 LSQODMMMSXHVCN-UHFFFAOYSA-N 0.000 description 1
- CQDAMYNQINDRQC-UHFFFAOYSA-N oxatriazole Chemical compound C1=NN=NO1 CQDAMYNQINDRQC-UHFFFAOYSA-N 0.000 description 1
- CDXVUROVRIFQMV-UHFFFAOYSA-N oxo(diphenoxy)phosphanium Chemical compound C=1C=CC=CC=1O[P+](=O)OC1=CC=CC=C1 CDXVUROVRIFQMV-UHFFFAOYSA-N 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- NRZWYNLTFLDQQX-UHFFFAOYSA-N p-tert-Amylphenol Chemical compound CCC(C)(C)C1=CC=C(O)C=C1 NRZWYNLTFLDQQX-UHFFFAOYSA-N 0.000 description 1
- NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000010713 partial hind limb paralysis Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- PMJHHCWVYXUKFD-UHFFFAOYSA-N penta-1,3-diene Chemical compound CC=CC=C PMJHHCWVYXUKFD-UHFFFAOYSA-N 0.000 description 1
- SLIUAWYAILUBJU-UHFFFAOYSA-N pentacene Chemical compound C1=CC=CC2=CC3=CC4=CC5=CC=CC=C5C=C4C=C3C=C21 SLIUAWYAILUBJU-UHFFFAOYSA-N 0.000 description 1
- GUVXZFRDPCKWEM-UHFFFAOYSA-N pentalene Chemical compound C1=CC2=CC=CC2=C1 GUVXZFRDPCKWEM-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 125000002080 perylenyl group Chemical group C1(=CC=C2C=CC=C3C4=CC=CC5=CC=CC(C1=C23)=C45)* 0.000 description 1
- CSHWQDPOILHKBI-UHFFFAOYSA-N peryrene Natural products C1=CC(C2=CC=CC=3C2=C2C=CC=3)=C3C2=CC=CC3=C1 CSHWQDPOILHKBI-UHFFFAOYSA-N 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NQFOGDIWKQWFMN-UHFFFAOYSA-N phenalene Chemical compound C1=CC([CH]C=C2)=C3C2=CC=CC3=C1 NQFOGDIWKQWFMN-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N piperidin-2-one Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000036316 preload Effects 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000006410 propenylene group Chemical group 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- DKORSYDQYFVQNS-UHFFFAOYSA-N propyl methanesulfonate Chemical compound CCCOS(C)(=O)=O DKORSYDQYFVQNS-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- LNKHTYQPVMAJSF-UHFFFAOYSA-N pyranthrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC3=C(C=CC=C4)C4=CC4=CC=C1C2=C34 LNKHTYQPVMAJSF-UHFFFAOYSA-N 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- BWESROVQGZSBRX-UHFFFAOYSA-N pyrido[3,2-d]pyrimidine Chemical compound C1=NC=NC2=CC=CN=C21 BWESROVQGZSBRX-UHFFFAOYSA-N 0.000 description 1
- 229960001327 pyridoxal phosphate Drugs 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000003235 pyrrolidines Chemical class 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- FMKFBRKHHLWKDB-UHFFFAOYSA-N rubicene Chemical compound C12=CC=CC=C2C2=CC=CC3=C2C1=C1C=CC=C2C4=CC=CC=C4C3=C21 FMKFBRKHHLWKDB-UHFFFAOYSA-N 0.000 description 1
- JWHOQZUREKYPBY-UHFFFAOYSA-N rubonic acid Natural products CC1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(=O)C(C)(C)C5CC(=O)C34C)C2C1)C(=O)O JWHOQZUREKYPBY-UHFFFAOYSA-N 0.000 description 1
- WEMQMWWWCBYPOV-UHFFFAOYSA-N s-indacene Chemical compound C=1C2=CC=CC2=CC2=CC=CC2=1 WEMQMWWWCBYPOV-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- CWXOAQXKPAENDI-UHFFFAOYSA-N sodium methylsulfinylmethylide Chemical compound [Na+].CS([CH2-])=O CWXOAQXKPAENDI-UHFFFAOYSA-N 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- PENHIDVQSIEBJM-ZDUSSCGKSA-N tert-butyl (3s)-3-(6-methyl-5-nitro-1-oxoisoquinolin-2-yl)pyrrolidine-1-carboxylate Chemical compound [O-][N+](=O)C=1C(C)=CC=C(C2=O)C=1C=CN2[C@H]1CCN(C(=O)OC(C)(C)C)C1 PENHIDVQSIEBJM-ZDUSSCGKSA-N 0.000 description 1
- YUXNFXSRESMZIT-SFHVURJKSA-N tert-butyl (3s)-3-[5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]pyrrolidine-1-carboxylate Chemical compound C=1C=C(C(F)(F)F)C(F)=CC=1CC(=O)NC=1C(C)=CC=C(C2=O)C=1C=CN2[C@H]1CCN(C(=O)OC(C)(C)C)C1 YUXNFXSRESMZIT-SFHVURJKSA-N 0.000 description 1
- IPKFEPRTJMDRDM-UHFFFAOYSA-N tert-butyl 2-(5-nitro-1-oxoisochromen-6-yl)acetate Chemical compound C1=COC(=O)C=2C1=C([N+]([O-])=O)C(CC(=O)OC(C)(C)C)=CC=2 IPKFEPRTJMDRDM-UHFFFAOYSA-N 0.000 description 1
- KUYMVWXKHQSIAS-UHFFFAOYSA-N tert-butyl 2-chloroacetate Chemical compound CC(C)(C)OC(=O)CCl KUYMVWXKHQSIAS-UHFFFAOYSA-N 0.000 description 1
- YTADUJSOIVCVSL-HXUWFJFHSA-N tert-butyl 4-[(2r)-2-[5-[[2-[3-fluoro-4-(trifluoromethyl)phenyl]acetyl]amino]-6-methyl-1-oxoisoquinolin-2-yl]propyl]piperazine-1-carboxylate Chemical compound C([C@@H](C)N1C(C2=CC=C(C)C(NC(=O)CC=3C=C(F)C(=CC=3)C(F)(F)F)=C2C=C1)=O)N1CCN(C(=O)OC(C)(C)C)CC1 YTADUJSOIVCVSL-HXUWFJFHSA-N 0.000 description 1
- QYJVBVKFXDHFPQ-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)-n-methylcarbamate Chemical compound NCCN(C)C(=O)OC(C)(C)C QYJVBVKFXDHFPQ-UHFFFAOYSA-N 0.000 description 1
- DJCMTZUQWODNFQ-UHFFFAOYSA-N tert-butyl n-[(4,4-difluorocyclohexyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1CCC(F)(F)CC1 DJCMTZUQWODNFQ-UHFFFAOYSA-N 0.000 description 1
- IUHLVCYWNNEMRU-UHFFFAOYSA-N tert-butyl n-methyl-n-[2-(6-methyl-5-nitro-1-oxoisoquinolin-2-yl)ethyl]carbamate Chemical compound CC1=CC=C2C(=O)N(CCN(C)C(=O)OC(C)(C)C)C=CC2=C1[N+]([O-])=O IUHLVCYWNNEMRU-UHFFFAOYSA-N 0.000 description 1
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 125000005207 tetraalkylammonium group Chemical group 0.000 description 1
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical group CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 1
- CXWXQJXEFPUFDZ-UHFFFAOYSA-N tetralin Chemical compound C1=CC=C2CCCCC2=C1 CXWXQJXEFPUFDZ-UHFFFAOYSA-N 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000004001 thioalkyl group Chemical group 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000005580 triphenylene group Chemical group 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90604907P | 2007-03-09 | 2007-03-09 | |
| US91808607P | 2007-03-15 | 2007-03-15 | |
| US91826107P | 2007-03-15 | 2007-03-15 | |
| US91812307P | 2007-03-15 | 2007-03-15 | |
| US91826007P | 2007-03-15 | 2007-03-15 | |
| US837007P | 2007-12-20 | 2007-12-20 | |
| US838607P | 2007-12-20 | 2007-12-20 | |
| US838507P | 2007-12-20 | 2007-12-20 | |
| US1067208P | 2008-01-10 | 2008-01-10 | |
| PCT/US2008/003175 WO2008112205A1 (en) | 2007-03-09 | 2008-03-07 | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010520875A true JP2010520875A (ja) | 2010-06-17 |
| JP2010520875A5 JP2010520875A5 (cg-RX-API-DMAC7.html) | 2011-03-31 |
Family
ID=39759833
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009552762A Pending JP2010520875A (ja) | 2007-03-09 | 2008-03-07 | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8093265B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2124562B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010520875A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101686680B (cg-RX-API-DMAC7.html) |
| CA (1) | CA2680275C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2124562T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2576643T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008112205A1 (cg-RX-API-DMAC7.html) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530304A (ja) * | 2006-03-16 | 2009-08-27 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
| JP2009542595A (ja) * | 2006-07-06 | 2009-12-03 | グラクソ グループ リミテッド | Ｐ２ｘ７受容体アンタゴニストとしての置換ｎ−フェニルメチル−５−オキソ−プロリン−２−アミドおよびそれらの使用方法 |
| JP2014520880A (ja) * | 2011-07-22 | 2014-08-25 | アクテリオン ファーマシューティカルズ リミテッド | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| JP2017520538A (ja) * | 2014-06-05 | 2017-07-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規キノリン誘導体及び神経変性疾患におけるそれらの使用 |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0709596A2 (pt) | 2006-03-16 | 2011-07-19 | Renovis Inc | compostos bicicloeteroarila como moduladores de p2x7 e seus usos |
| CA2645556C (en) | 2006-03-16 | 2016-05-24 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| US8212723B2 (en) * | 2008-08-27 | 2012-07-03 | Qualcomm Incorporated | Method and apparatus for determining at a predetermined granularity the direction and range of a transmitting mobile device |
| HK1203932A1 (en) | 2012-01-20 | 2015-11-06 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| WO2014091415A1 (en) | 2012-12-12 | 2014-06-19 | Actelion Pharmaceuticals Ltd | Indole carboxamide derivatives as p2x7 receptor antagonists |
| AR094053A1 (es) | 2012-12-18 | 2015-07-08 | Actelion Pharmaceuticals Ltd | Derivados de indol carboxamida como antagonistas del receptor p2x₇ |
| US9388197B2 (en) | 2013-01-22 | 2016-07-12 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as P2X7 receptor antagonists |
| WO2014115078A1 (en) | 2013-01-22 | 2014-07-31 | Actelion Pharmaceuticals Ltd | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| TWI825637B (zh) | 2021-03-31 | 2023-12-11 | 美商輝瑞股份有限公司 | 啶－１，６（２ｈ，７ｈ）－二酮 |
| WO2025057074A1 (en) * | 2023-09-13 | 2025-03-20 | Suven Life Sciences Limited | N-aryl benzamide derivatives as p2x7 receptor antagonists |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006102610A2 (en) * | 2005-03-24 | 2006-09-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| JP2009530302A (ja) * | 2006-03-16 | 2009-08-27 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
| JP2009530304A (ja) * | 2006-03-16 | 2009-08-27 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
| JP2009541206A (ja) * | 2006-03-16 | 2009-11-26 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US588736A (en) * | 1897-08-24 | Egg-tester | ||
| FR2450E (fr) | 1903-02-09 | 1904-04-07 | Sulzer Freres Soc | Palier pour pompes et autres machines analogues |
| DE2343984A1 (de) | 1973-08-31 | 1975-03-13 | Hoechst Ag | Wasserunloesliche disazomethinfarbstoffe, verfahren zu ihrer herstellung und ihre verwendung |
| US3950343A (en) * | 1973-11-06 | 1976-04-13 | Ayerst, Mckenna And Harrison Ltd. | Pyrroloisoquinoline derivatives |
| US3900477A (en) * | 1973-11-06 | 1975-08-19 | Ayerst Mckenna & Harrison | 5-amino-and 5-hydrazinodihydropyrroloisoquinoline derivatives |
| SU749832A1 (ru) | 1978-03-24 | 1980-07-23 | Предприятие П/Я М-5885 | Способ получени амино- -оксифенантридонов |
| GB2044254B (en) | 1979-01-26 | 1983-01-26 | Wyeth John & Brother Ltd | Piperidine derivatives |
| EP0093488A3 (en) | 1982-03-18 | 1984-05-23 | Beecham Group Plc | Nortropyl benzopyrrolinone compounds, process for their preparation and pharmaceutical compositions containing them |
| DE3368061D1 (en) | 1982-05-11 | 1987-01-15 | Beecham Group Plc | Azabicycloalkane derivatives, their preparation and medicaments containing them |
| EP0101641A3 (en) | 1982-07-22 | 1984-03-28 | Beecham Group Plc | Sulfonylamino-aza-bicyclo-alkyl derivatives |
| JPH0731405B2 (ja) | 1986-05-02 | 1995-04-10 | キヤノン株式会社 | 電子写真感光体 |
| JP2699511B2 (ja) | 1988-01-29 | 1998-01-19 | 武田薬品工業株式会社 | 置換アミン類 |
| US4897391A (en) * | 1988-06-17 | 1990-01-30 | Schering Corporation | Tricyclic anti-allergy, antiinflammatory and anti-hyperproliferative compounds |
| US5776963A (en) | 1989-05-19 | 1998-07-07 | Hoechst Marion Roussel, Inc. | 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5140023A (en) | 1990-04-27 | 1992-08-18 | G. D. Searle & Co. | Azatetracycle compounds |
| HU213136B (en) | 1990-08-14 | 1997-02-28 | Kyorin Seiyaku Kk | Process for producing fluoroethyl camptothecin derivatives and pharmaceutical compositions containing them |
| KR920008026A (ko) | 1990-10-24 | 1992-05-27 | 오노 화아마슈티칼 캄파니 리미팃드 | 이소퀴놀리논 유도체 또는 이의 무독성 산부가염 또는 이의 수화물, 이의 제조방법 및 이를 포함하는 약제 조성물 |
| JPH04270273A (ja) | 1991-02-25 | 1992-09-25 | Kyorin Pharmaceut Co Ltd | チアゾリジン−２，４−ジオン誘導体とその塩及びその製造法 |
| EP0502575A1 (en) | 1991-03-06 | 1992-09-09 | Merck & Co. Inc. | Substituted 1-(2H)-isoquinolinones |
| AU1532492A (en) | 1991-04-18 | 1992-11-17 | Dr. Lo Zambeletti S.P.A. | Use of heterocyclic compounds for the treatment of inflammatory pain |
| US5491148A (en) * | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
| DE69209576D1 (de) | 1991-05-10 | 1996-05-09 | Takeda Chemical Industries Ltd | Pyridinderivate, deren Herstellung und Anwendung |
| GB9122859D0 (en) | 1991-10-28 | 1991-12-11 | Smithkline Beecham Plc | Novel compounds |
| US5272158A (en) | 1991-10-29 | 1993-12-21 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| JPH06295078A (ja) | 1992-04-24 | 1994-10-21 | Canon Inc | 電子写真感光体、該電子写真感光体を備えた電子写真装置並びにファクシミリ |
| US5840903A (en) | 1992-07-27 | 1998-11-24 | G. D. Searle & Co. | 4-aminomethyl-1-azaadamantane derived benzamides |
| US5354757A (en) | 1992-12-15 | 1994-10-11 | G. D. Searle & Co. | Azanoradamantanes |
| AU7102394A (en) | 1993-06-09 | 1995-01-03 | Smithkline Beecham Corporation | Bicyclic fibrinogen antagonists |
| DE4345266C2 (de) | 1993-10-04 | 1996-12-19 | Luitpold Pharma Gmbh | Heterocyclische Carbamate, Verfahren zu ihrer Herstellung und Arzneimittel |
| AU694465B2 (en) | 1993-12-27 | 1998-07-23 | Eisai Co. Ltd. | Anthranilic acid derivative |
| US5530018A (en) | 1994-02-04 | 1996-06-25 | G. D. Searle & Co. | Meso-azanoradamantanes |
| GB9409150D0 (en) | 1994-05-09 | 1994-06-29 | Black James Foundation | Cck and gastrin receptor ligands |
| US5500442A (en) | 1994-06-10 | 1996-03-19 | American Home Products Corporation | Cyclobut-3-ene-1,2-dione derivatives as smooth muscle relaxants |
| US5644144A (en) * | 1994-09-23 | 1997-07-01 | Advanced Micro Devices, Inc. | Device and method for programming a logic level within an integrated circuit using multiple mask layers |
| US5631280A (en) | 1995-03-29 | 1997-05-20 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| AU714072B2 (en) | 1995-06-29 | 1999-12-16 | Banyu Pharmaceutical Co., Ltd. | Combinations of inhibitors of farnesyl-protein transferase |
| US5723411A (en) * | 1995-10-31 | 1998-03-03 | E. I. Du Pont De Nemours And Company | Herbicidal pyridazinones |
| JP3285746B2 (ja) * | 1995-11-24 | 2002-05-27 | 株式会社資生堂 | フェニレンジアミン誘導体及びラジカルスカベンジャー、脳梗塞抑制剤、脳浮腫抑制剤 |
| US5756518A (en) | 1996-04-02 | 1998-05-26 | Kowa Co., Ltd. | Phenylene derivatives |
| AU2980797A (en) | 1996-06-11 | 1998-01-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Fused heterocyclic compounds and medicinal uses thereof |
| ES2271971T3 (es) | 1996-07-25 | 2007-04-16 | Biogen Idec Ma Inc. | Inhibidores de la adhesion celular. |
| US6429212B1 (en) | 1996-08-16 | 2002-08-06 | Ishihara Sangyo Kaisha Ltd. | Medicinal composition |
| DE19650975A1 (de) | 1996-12-09 | 1998-06-10 | Basf Ag | Neue heterocyclisch substituierte Benzamide und deren Anwendung |
| DE19653647A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| DE19653645A1 (de) | 1996-12-20 | 1998-06-25 | Hoechst Ag | Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung |
| US6262068B1 (en) * | 1997-02-21 | 2001-07-17 | Bristol-Myers Squibb Company | Lactam derivatives as antiarrhythmic agents |
| DE59802394D1 (de) | 1997-05-09 | 2002-01-24 | Hoechst Ag | Substituierte Diaminocarbonsäuren |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| ATE267828T1 (de) * | 1997-10-07 | 2004-06-15 | Ortho Mcneil Pharm Inc | Dipyridoimidazolderivate zur behandlung von störungen des zentralen nervensystems |
| CA2307030A1 (en) | 1997-10-24 | 1999-05-06 | Mervyn Thompson | Substituted isoquinoline derivatives and their use as anticonvulsants |
| JP3337992B2 (ja) * | 1997-11-04 | 2002-10-28 | ファイザー製薬株式会社 | ５−置換ピコリン酸化合物及びその製造方法 |
| JPH11171774A (ja) | 1997-12-05 | 1999-06-29 | Kyowa Hakko Kogyo Co Ltd | 血球増多剤 |
| SE9704546D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704545D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| SE9704544D0 (sv) | 1997-12-05 | 1997-12-05 | Astra Pharma Prod | Novel compounds |
| JP2002501909A (ja) | 1998-01-29 | 2002-01-22 | ドクター・レディーズ・リサーチ・ファウンデーション | 新規なアルカン酸およびその医薬における使用、並びにその製造方法、およびそれを含有する薬学的組成物 |
| CA2332239A1 (en) | 1998-05-15 | 1999-11-25 | Guilford Pharmaceuticals Inc. | Fused tricyclic compounds which inhibit parp activity |
| GB9817424D0 (en) * | 1998-08-11 | 1998-10-07 | Smithkline Beecham Plc | Novel compounds |
| SE9901875D0 (sv) | 1999-05-25 | 1999-05-25 | Astra Pharma Prod | Novel compounds |
| GB9915995D0 (en) | 1999-07-09 | 1999-09-08 | Ahmed S | Non-steroidal sulphamate compounds for use as oestrone sulphatase inhibitors |
| JP2003506387A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | カリウムチャンネルオープナーとしてのベンズアニリド |
| JP2003506388A (ja) | 1999-08-04 | 2003-02-18 | アイカゲン インコーポレイテッド | 疼痛および不安症を処置または予防するための方法 |
| GB9919411D0 (en) | 1999-08-18 | 1999-10-20 | Zeneca Ltd | Chemical compounds |
| WO2001021615A1 (fr) | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
| JP2001172258A (ja) | 1999-12-17 | 2001-06-26 | Sumitomo Pharmaceut Co Ltd | 神経網膜変性疾患の治療薬 |
| SE9904652D0 (sv) * | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| US6780858B2 (en) | 2000-01-13 | 2004-08-24 | Tularik Inc. | Antibacterial agents |
| GB0005366D0 (en) * | 2000-03-06 | 2000-04-26 | Xenova Ltd | Pharmaceutical compounds |
| AU2001249399A1 (en) | 2000-03-24 | 2001-10-08 | Cor Therapeutics, Inc. | Isoquinolone inhibitors of factor xa |
| AU2001273099A1 (en) | 2000-07-13 | 2002-01-30 | Guilford Pharmaceuticals Inc. | Substituted 4,9-dihydrocyclopenta(imn) phenanthridine-5-ones, derivatives thereof and their uses |
| US6603013B2 (en) * | 2000-07-17 | 2003-08-05 | Merck & Co., Inc. | Heterogeneously catalyzed process for cross coupling alkenyl halides with boronic acids |
| EP1368366A1 (en) | 2001-02-07 | 2003-12-10 | Celltech R & D Limited | Non-natural nucleotides and dinucleotides |
| JP2002338837A (ja) | 2001-05-16 | 2002-11-27 | Fuji Photo Film Co Ltd | 新規化合物、色素、インク組成物、インクジェット用インク、インクジェット記録方法、及び熱転写色素 |
| WO2002094790A1 (en) | 2001-05-23 | 2002-11-28 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| AU2002355732B2 (en) | 2001-08-01 | 2006-11-09 | Merck Sharp & Dohme Corp. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| US7074805B2 (en) * | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| MXPA04008073A (es) | 2002-02-20 | 2004-11-26 | Abbott Lab | Compuestos azabiciclicos fusionados que inhiben el receptor de subtipo 1 (vr1) del receptor de vainilloide. |
| GB0206876D0 (en) | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| US8247424B2 (en) | 2002-03-26 | 2012-08-21 | Zentopharm Gmbh | Fredericamycin derivatives |
| DE10215316C1 (de) | 2002-04-02 | 2003-12-18 | Schering Ag | Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer |
| PL372890A1 (en) | 2002-05-03 | 2005-08-08 | Schering Aktiengesellschaft | Thiazolidinones and the use thereof as polo-like kinase inhibitors |
| CA2493230A1 (en) | 2002-07-22 | 2004-01-29 | Asahi Kasei Pharma Corporation | 5-substituted isoquinoline derivative |
| DE10238865A1 (de) | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| JP2004203813A (ja) | 2002-12-26 | 2004-07-22 | Tokuyama Corp | クロメン化合物 |
| PA8591801A1 (es) * | 2002-12-31 | 2004-07-26 | Pfizer Prod Inc | Inhibidores benzamidicos del receptor p2x7. |
| SG2012000667A (en) | 2003-01-08 | 2015-03-30 | Univ Washington | Antibacterial agents |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| EP2308848A1 (en) | 2003-02-03 | 2011-04-13 | Janssen Pharmaceutica NV | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| AU2004234087A1 (en) | 2003-04-28 | 2004-11-11 | Tibotec Pharmaceuticals Ltd. | HIV integrase inhibitors |
| ES2281801T3 (es) * | 2003-05-12 | 2007-10-01 | Pfizer Products Inc. | Inhibidores benzamida del receptor p2x7. |
| CN1566099A (zh) * | 2003-06-13 | 2005-01-19 | 中国科学院上海药物研究所 | 异喹啉－1,3,4－三酮类化合物、制备方法及其用途 |
| WO2004113345A1 (ja) | 2003-06-20 | 2004-12-29 | Japan Tobacco Inc. | 縮合ピロール化合物及びその医薬用途 |
| US7390820B2 (en) * | 2003-08-25 | 2008-06-24 | Amgen Inc. | Substituted quinolinone derivatives and methods of use |
| US7432281B2 (en) * | 2003-10-07 | 2008-10-07 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| US7491794B2 (en) * | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| TW200530235A (en) * | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
| JP2005232175A (ja) | 2004-01-21 | 2005-09-02 | Asahi Kasei Pharma Kk | ５−置換イソキノリン医薬 |
| CA2553968A1 (en) * | 2004-01-23 | 2005-08-11 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments of inflammatory and neuropathic pain |
| US7576099B2 (en) * | 2005-02-28 | 2009-08-18 | Renovis, Inc. | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| WO2007109154A2 (en) * | 2006-03-16 | 2007-09-27 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
-
2008
- 2008-03-07 US US12/075,111 patent/US8093265B2/en not_active Expired - Fee Related
- 2008-03-07 CN CN200880014110.6A patent/CN101686680B/zh active Active
- 2008-03-07 DK DK08726672.2T patent/DK2124562T3/en active
- 2008-03-07 JP JP2009552762A patent/JP2010520875A/ja active Pending
- 2008-03-07 WO PCT/US2008/003175 patent/WO2008112205A1/en not_active Ceased
- 2008-03-07 EP EP08726672.2A patent/EP2124562B1/en not_active Not-in-force
- 2008-03-07 ES ES08726672.2T patent/ES2576643T3/es active Active
- 2008-03-07 CA CA2680275A patent/CA2680275C/en not_active Expired - Fee Related
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006102610A2 (en) * | 2005-03-24 | 2006-09-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| WO2006102588A1 (en) * | 2005-03-24 | 2006-09-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| JP2009530302A (ja) * | 2006-03-16 | 2009-08-27 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
| JP2009530304A (ja) * | 2006-03-16 | 2009-08-27 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
| JP2009541206A (ja) * | 2006-03-16 | 2009-11-26 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009530304A (ja) * | 2006-03-16 | 2009-08-27 | レノビス， インコーポレイテッド | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
| JP2009542595A (ja) * | 2006-07-06 | 2009-12-03 | グラクソ グループ リミテッド | Ｐ２ｘ７受容体アンタゴニストとしての置換ｎ−フェニルメチル−５−オキソ−プロリン−２−アミドおよびそれらの使用方法 |
| JP2014520880A (ja) * | 2011-07-22 | 2014-08-25 | アクテリオン ファーマシューティカルズ リミテッド | Ｐ２ｘ７受容体アンタゴニストとしての複素環アミド誘導体 |
| JP2017520538A (ja) * | 2014-06-05 | 2017-07-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規キノリン誘導体及び神経変性疾患におけるそれらの使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2124562A1 (en) | 2009-12-02 |
| US8093265B2 (en) | 2012-01-10 |
| EP2124562A4 (en) | 2010-03-10 |
| CA2680275A1 (en) | 2008-09-18 |
| WO2008112205A1 (en) | 2008-09-18 |
| HK1136967A1 (zh) | 2010-07-16 |
| DK2124562T3 (en) | 2016-08-01 |
| CN101686680A (zh) | 2010-03-31 |
| US20080287415A1 (en) | 2008-11-20 |
| CN101686680B (zh) | 2015-12-09 |
| ES2576643T3 (es) | 2016-07-08 |
| EP2124562B1 (en) | 2016-04-20 |
| CA2680275C (en) | 2016-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010520875A (ja) | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 | |
| JP5306986B2 (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 | |
| JP5240941B2 (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 | |
| JP5306987B2 (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 | |
| JP2008534511A (ja) | Ｐ２ｘ７調節因子としてのビシクロヘテロアリール化合物およびその使用 | |
| WO2007109182A2 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2007109154A2 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| WO2007109201A2 (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| CN101443315B (zh) | 作为p2x7调节剂的双环杂芳基化合物及其应用 | |
| HK1136967B (en) | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof | |
| JP2009541205A (ja) | Ｐ２ｘ７調節因子としてのビシクロへテロアリール化合物およびその使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110207 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110207 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120125 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130304 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130516 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130523 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130704 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130812 |